Benjamin Romick, MD
Interventional Cardiology · San Francisco, CANPI 1497774434
Payments from drug & device makers
Across 241 payments — averaging $113.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$12K
- Medtronic$7K
- Abbott$4K
- Philips North America LLC$654
- Amgen$405
- Cardiovascular Systems Inc.$356
- plus $3K from 24 others
What the payments were for
- Speaking & faculty fees$5003%
- Travel & lodging$5,89638%
- Food & beverage$9,05959%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 14 | $12,204 |
| Medtronic(2 entities) | 71 | $7,064 |
| Abbott | 32 | $4,035 |
| Philips North America LLC | 5 | $654 |
| Amgen | 15 | $405 |
| Cardiovascular Systems Inc. | 5 | $356 |
| Heartflow, Inc. | 6 | $292 |
| Acist Medical Systems, Inc. | 2 | $254 |
| Boston Scientific | 12 | $227 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $199 |
| Boehringer Ingelheim | 10 | $190 |
| Abiomed | 4 | $185 |
| Johnson & Johnson | 13 | $168 |
| Shockwave Medical, Inc | 4 | $159 |
| Edwards Lifesciences | 1 | $120 |
| Sanofi-aventis U.S. LLC | 5 | $107 |
| Regeneron Healthcare Solutions, Inc. | 3 | $93 |
| E.r. Squibb & Sons, L.L.C. | 4 | $91 |
| Novartis | 5 | $86 |
| AstraZeneca | 4 | $77 |
| Chiesi USA, Inc. | 4 | $58 |
| Livanova USA, Inc. | 1 | $41 |
| Amarin Pharma, Inc. | 2 | $35 |
| Irhythm Technologies, Inc. | 2 | $31 |
| Teleflex LLC | 1 | $29 |
| Cathworks, Inc. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $22 |
| Lundbeck LLC | 1 | $22 |
| Bardy Diagnostics, Inc. | 1 | $21 |
| Siemens Medical Solutions USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$2,681
- Micra$1,797
- RESOLUTE ONYX$553
- Spectranetics Undiv$500
- SelectSecure$449
- Resolute$318
- ONYX FRONTIER$177
- Confirm Rx$176
- SYMPLICITY G3$174
- HD-IVUS$166
- QUADRA ALLURE MP$160
- CoreValve Evolut$158
- Diamondback Coronary$150
- Xience Sierra Coronary Stent$131
- ENSITE$125
- Edwards SAPIEN 3 Transcatheter Heart Valve$120
- Vascular Lithotripsy$102
How this compares
$27,267 in reported general payments places this provider in the 70th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 266 | $364,751 |
| XareltoRivaroxaban | 158 | $224,396 |
| MultaqDronedarone Hcl | 30 | $62,965 |
| JardianceEmpagliflozin | 35 | $37,033 |
| EntrestoSacubitril/Valsartan | 24 | $29,638 |
| FarxigaDapagliflozin Propanediol | 19 | $24,548 |
| Repatha SureclickEvolocumab | 16 | $14,870 |
| LinzessLinaclotide | 12 | $6,384 |
| Metoprolol Succinate | 233 | $4,246 |
| Atorvastatin Calcium | 389 | $3,963 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 11 | $3,455 |
| Losartan Potassium | 154 | $2,039 |
| Eplerenone | 21 | $1,575 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 14 | $1,489 |
| Carvedilol | 141 | $1,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $168 | $224,396158 claims |
| Sanofi-aventis U.S. LLCMultaq | $107 | $62,96530 claims |
| Boehringer IngelheimJardiance | $190 | $37,03335 claims |
| NovartisEntresto | $86 | $29,63824 claims |
| AstraZenecaFarxiga | $77 | $24,54819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in San Francisco
- Sammy ElmariahSan Francisco$4.2M
- Jacob MishellSan Francisco$1.7M
- Kendrick ShunkSan Francisco$1.2M
- Chun LinSan Francisco$1M
- Yousif AhmadSan Francisco$380K
- Rajendra MakkarWest Hollywood$16.6M
- Fahed BitarCovina$9.9M
- Rahul SharmaStanford$6.6M
- Matthew Pricela Jolla$5.8M
- David LeeStanford$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.